SNY
Sanofi ADR
NASDAQ: SNY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$42.24
+0.84% today
Updated 2026-10-28
Market cap
$97.31B
P/E ratio
21.37
P/S ratio
1.99x
EPS (TTM)
$1.90
Dividend yield
10.20%
52W range
$39 – $50
Volume
2.9M
WallStSmart proprietary scores
51
out of 100
Grade: C
Hold
Investment rating
4.0
Growth
C5.3
Quality
C+6.0
Profitability
B4.7
Valuation
C5/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$58.00
+37.31%
12-Month target
$47.91
+13.42%
Intrinsic (DCF)
$50.72
Margin of safety
+7.28%
0 Strong Buy5 Buy5 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $3.90B — positive
+ Revenue growth 14.60% QoQ
+ Debt/equity 0.34x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $40.56B | $41.62B | $44.29B | $46.72B | $48.92B | $52.4B |
| Net income | $8.37B | $5.40B | $5.56B | $7.81B | $343.00M | — |
| EPS | — | — | — | — | $1.90 | $8.48 |
| Free cash flow | $8.32B | $7.35B | $5.89B | $10.14B | $3.90B | — |
| Profit margin | 20.64% | 12.98% | 12.55% | 16.72% | 8.09% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-10 | SANOFI | Sale | 494,800 | — |
| 2026-08-10 | SANOFI | Sale | 177,978 | — |
| 2026-08-10 | SANOFI | Buy | 494,800 | — |
Peer comparison
Smart narrative
Sanofi ADR trades at $42.24. representing a P/E of 21.37x trailing earnings. Our Smart Value Score of 51/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. TTM revenue stands at $48.92B. with profit margins at 8.09%. Our DCF model estimates intrinsic value at $50.72.
Frequently asked questions
What is Sanofi ADR's stock price?
Sanofi ADR (SNY) trades at $42.24, on a P/E of 21.4x and a P/S of 2.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sanofi ADR overvalued?
Sanofi ADR carries a Smart Value Score of 51/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $50.72 versus the $42.24 price, a 7.3% margin of safety on a cash flow basis.
What is the price target of Sanofi ADR (SNY)?
The 12-month analyst consensus target is $58.00, about 37.3% above the current $42.24. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of SNY by 2030?
Our research-backed model puts the 2030 base case at $325.65, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Sanofi ADR (SNY)?
Our DCF model estimates intrinsic value at $50.72, a +7.3% margin of safety versus today's $42.24. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Sanofi ADR's revenue?
Sanofi ADR's trailing twelve-month revenue is $48.92B, and our model projects it reaching about $65.90B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.99x
ROE5.72%
Beta0.28
50D MA$42.67
200D MA$44.63
Shares out2.40B
Float2.16B
Short ratio—
Avg volume2.9M
Performance
1 week+0.67%
1 month+3.68%
3 months-1.52%
YTD-12.84%
1 year-16.65%
3 years—
5 years—